Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Non Small Cell Lung Cancer
PFS, Progression free survival, may 2020- may 2021 (1 year)
OS, Overall survival, may 2020- may 2021 (1 year)|ORR, To measure the patients's overall response rate, may 2020- may 2021 (1 year)
Main enrolled criteria:

Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using